Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Eiermann, W; Bergh, J; Cardoso, F; Conte, P; Crown, J; Curtin, N J; Gligorov, J; Gusterson, B; Joensuu, H; Linderholm, B K; Martin, M; Penault-Llorca, F; Pestalozzi, B C; Razis, E; Sotiriou, C; Tjulandin, S; Viale, G (2012). Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. Breast, 21(1):20-26.

Pestalozzi, B C; et al; Gelber, R D; Viale, G (2008). Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Annals of Oncology, 19(11):1837-1841.

Viale, G; Regan, M M; Maiorano, E; Stahel, R A (2008). Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Journal of Clinical Oncology, 26(9):1404-1410.

Viale, G; Giobbie-Hurder, A; Regan, M M; Stahel, R A (2008). Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. Journal of Clinical Oncology, 26(34):5569-5575.

Ravaioli, A; Monti, F; Regan, M M; Maffini, F; Mastropasqua, M G; Spataro, V; Castiglione-Gertsch, M; Panzini, I; Gianni, L; Goldhirsch, A; Coates, A; Price, K N; Gusterson, B A; Viale, G (2008). p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. Annals of Oncology, 19(4):660-668.

This list was generated on Mon Sep 23 18:04:24 2019 CEST.